Dose Escalation of IPI-493 in Hematologic Malignancies

• Status: Terminated
• Trial end date: 2011-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety, determine the maximum tolerated dose (MTD) and schedule of IPI-493 in patients with hematologic malignancies.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Infinity Pharmaceuticals, Inc.
• Treatments: Geldanamycin

Criteria

Inclusion Criteria:

• >/=18 years old

• ECOG 0-1

• confirmed hematological malignancy

• refractory to available therapy or for which no therapy is available

• adequate hepatic, renal function

Exclusion Criteria:

• active CNS malignancy

• prolonged QT interval

• significant GI/liver disease

• other serious concurrent illness or medical condition